Skip to main content
. 2022 Dec;17(12):1754–1762. doi: 10.2215/CJN.08900722

Figure 1.

Figure 1.

Estimated relative treatment effects of combination treatment with the renin-angiotensin-aldosterone system and sodium-glucose cotransporter-2 inhibitors on key outcomes. 95% CI, 95% confidence interval; DAPA-CKD, Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease; REIN, Ramipril Efficacy in Nephropathy.